NEWSROOM

September 24th, 2025 - NxGEN Vector Solutions Named “Top Gene Therapy Solution 2025” by Life Sciences Review

Washington, D.C. — NxGEN Vector Solutions, a leader in next-generation gene therapy vector design, today announced it has been recognized as the “Top Gene Therapy Solution 2025” by Life Sciences Review. This annual award is presented to one company demonstrating outstanding innovation, scalability, and impact in advancing the future of gene therapy.

To determine the recipient, Life Sciences Review conducted a multi-stage evaluation. The process began with industry nominations from qualified subscribers, highlighting organizations driving progress in viral vector development, regulatory readiness, and clinical scalability. From these nominations, the editorial team conducted an in-depth review based on design innovation, manufacturing scalability, clinical-stage performance, and regulatory standards.

In the final stage, input was sought from domain experts — including Directors of Gene Therapy Programs, Chief Scientific Officers, and Heads of Translational Medicine. Drawing on this collective expertise, NxGEN Vector Solutions was selected for its exceptional contributions in overcoming immune barriers and enabling durable, safe gene therapies through its patented CpG-depletion technology.

“We are honored to receive this recognition from Life Sciences Review,” said Susan Faust, CEO of NxGEN Vector Solutions. “This award underscores our team’s commitment to transforming gene therapy by delivering safer, longer-lasting treatments for patients with genetic disorders.”

NxGEN’s recognition will be featured in the November 2025 issue of Life Sciences Review, which will include a profile of the company’s platform and vision for the future of gene therapy.

Click here to view the award

March 1st, 2025 - The National Institute of Neurological Disorders and Stroke (NINDS) held a workshop titled “Next generation strategies for gene-targeted therapies of central nervous system (CNS) disorders” in September 2019 in Bethesda, MD, USA.

The meeting brought together a multi-disciplinary group of experts in the field of CNS-directed gene-targeted therapy delivery from academia, industry, advocacy, and the government. The group was charged with identifying the key challenges and gaps in this evolving field, as well as suggesting potential solutions.

“Strategies to evade an immune response

Workshop participants discussed concerns over the immune response to AAV vector DNA sequences and methods to avoid it. Toll-like receptor 9 (TLR9) functions to detect foreign DNA and stimulates immune responses. TLR9 binds to unmethylated CpG motifs, which are frequently enriched in codon-optimized transgenes and strong ubiquitous promoters. Modification of AAV vector sequences to decrease CpG motifs can reduce innate immune responses and help with long-term transgene expression in the mouse skeletal muscle (Faust et al., 2013). Also, AAV vector sequences can be engineered to include short DNA oligonucleotides that inhibit TLR9 activation, reducing immune responses in the mouse liver, muscle, and retinas, as well as in pig retinas.”

Click here to read the published workshop document.

Click here to read Faust et al., “CpG-depleted adeno-associated vectors evade immune detection” JCI, 2013.

December 26th, 2024 - Read the article entitled ‘Gene Therapy Researcher’s Patent Dispute Cleared Against UPenn, Program Director’ published in The Legal Intelligencer.

Click here to read the article.

November 1st, 2024 - Read the article entitled ‘Penn Dodges Single Claim in Gene-Therapy Scientist’s Patent Suit’ published in Bloomberg Law.

Click here to read the article.

August 7th, 2024 - Read the article entitled ‘Penn Gene Therapy Program and Director to Depart University, Transfer to External Companies’ published in The Daily Pennsylvanian.

Click here to read the article

March 25th, 2024 - Read the article entitled ‘Former Penn Employee Sues Gene Therapy Director, Alleging ‘Unethical and Illegal Conduct’” published in The Daily Pennsylvanian.

Click here to read the article

January 30th, 2024 - Read the article entitled, ‘Lawsuit accuses Penn and gene therapy pioneer Dr. James Wilson of illegal conduct and sabotage’ published in the Philadelphia Business Journal concerning a federal lawsuit filed by NxGEN Vector Solutions against the University of Pennsylvania and James M. Wilson.

Click here to read the article.

January 27th, 2024 - A briefing document from the FDA for the Cellular, Tissue, and Gene Therapies Advisory Committee Meeting entitled, “Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy” (September 2021), recognizes the importance of incorporating NxGEN’s Transformative Technology into AAV vectors to evade the immune system for durable transgene expression.

The contribution of CpG dinucleotides in the vector genome in activating the innate immune mechanisms upon cellular entry is first mentioned on page 14 of the briefing. Section 2.4.2 goes into more detail on TLR9-dependent immune induction and recommends “codon modification to remove CpGs” as a strategy to circumvent CpG-mediated immune activation (page 16). 

Click here to read the Briefing Document

November 23rd, 2023 - NxGEN Vector Solutions attended the Washington Post Improving Patient Care live event program, at the Post’s D.C. headquarters.

This exclusive invite only event was a Symposium featuring panel conversations on the state of the U.S. Health Care System, the cost of prescription medication, and the ways to improve the patient experience hosted by Senator Susan Collins, Senator Jeanne Shaheen, Avik Roy, Matthew Fiedler, and Davis Liu.

September 27th, 2023 - NxGEN Vector Solutions attended the Washington Post Entrepreneurial Resilience live event program, at the Post’s D.C. headquarters. 

This exclusive invite-only event was a series of discussions about challenges and opportunities for small businesses in today’s economic climate.